Loading…
Loading…
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.
Simplify High Yield ETF (NYSEARCA:CDX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 366,043 shares, an increase of 1,869.9% from the February 26th total of 18,582 shares. Approximately 1.7% of the company's shares are sold short. Based on
AE Wealth Management LLC boosted its stake in shares of Simplify High Yield ETF (NYSEARCA:CDX) by 20.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,042,223 shares of the company's stock after acquiring an additional 179,543 shares during the period. AE Wealth Management LLC
NEW YORK--(BUSINESS WIRE)--Simplify Asset Management announces that it expects to deliver capital gains distributions across ten ETFs.
VettaFi recently sat down with Christopher Getter of Simplify Asset Management to discuss the role of private credit in portfolios and the unique structure of the Simplify Private Credit Strategy ETF (PCR), which is currently yielding 12.27%.
The Simplify High Yield ETF offers a defensive approach to high-yield investing, using proprietary hedges to dampen credit-driven drawdowns. CDX employs swaps, credit default swaps, and options to manage risk, aiming to limit losses during market stress while accepting some upside lag in rallies. Recent market events have shown CDX's hedges can reduce losses compared to traditional high-yield ETFs, though it may underperform in strong credit markets.
Simplify High Yield ETF offers an alternative HY strategy, mixing synthetic exposure with a quality/junk hedge to maximize income and manage credit risk. An ambitious claim, yet so far it has delivered alpha versus classic HY funds. But if every return comes with risk, where is it here? This comes from opportunistic management using synthetic instruments and alternative strategies, which add more uncertainty than passive ETFs.
CDX ETF has outperformed peers and delivered strong returns, validating its unique quality/junk equity hedge strategy for high-yield bond exposure. Recent volatility in April highlighted the risks of basis mismatch between credit and equity hedges, but the fund ultimately recovered well. However, I am concerned by signs of 'mandate creep,' as Simplify's portfolio managers have taken positions outside the fund's stated strategy, increasing operational risk.
SEC filings for CDX aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.